On May 9, 2017 Kymab Group Limited ("Kymab"), a leading human monoclonal antibody biopharmaceutical group, reported the appointment of Dr Sonia Quaratino as its first Chief Medical Officer (Press release, Kymab, MAY 9, 2017, View Source [SID1234537009]). Dr Quaratino will manage the clinical development of the Group’s expanding therapeutic antibody portfolio.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Dr Quaratino is an immunologist and joins Kymab from Novartis, where she has served as Global Clinical Program Leader – Transitional Clinical Oncology, responsible for the clinical development of proprietary therapeutic antibody programmes in immuno-oncology.
Prior to her role with Novartis, Dr Quaratino was Senior Medical Director and Immunology Advisor at Merck Serono, where she was responsible for the clinical development of various immunomodulators. Dr Quaratino also has over 20 years of professional experience in biomedical research in UK academic institutions including Imperial College London and the University of Southampton.
"I am delighted to welcome Sonia to Kymab," says Dr David Chiswell, CEO of Kymab, on the appointment. "With her demonstrated track record in clinical development and medical affairs, Sonia is a superb addition to Kymab‘s management team as we prepare for our first clinical trials. Sonia’s deep understanding of the global environment in clinical research complement those of Dr Arndt Schottelius, our new Executive VP of R&D who recently joined us from Morphosys.
"These two key appointments add a high calibre of depth and provide further validation to our burgeoning and advancing R&D pipeline."
Dr Sonia Quaratino, newly appointed Chief Medical Officer of Kymab added: "Kymab’s emerging human antibody pipeline provides great potential to improve patient treatment options in our four main therapeutic areas of focus: immuno-oncology; auto-immunity; haematology and infectious disease. The Kymouse technology that underpins the company contains a full set of human immunoglobulin light and heavy chain genes that can produce 10 trillion different antibodies, thus significantly increasing the chances of finding new best-in-class antibodies. I am pleased and proud to be joining the Kymab team."
Dr Quaratino has an extensive professional background which includes a Medical Degree and a Doctorate in Hematology-Oncology from the University of Palermo, Italy and a Ph.D. in Immunology from Imperial College London, UK. For a number of years Sonia was a Professor of Immunology at the University of Southampton, a leading institution for innovative research. During her time in Southampton her focus was on the pathogenic mechanisms underlying chronic inflammatory diseases and the interface between autoimmunity and cancer.
Notes to Editors
Issued 9 May, 2017
Kymab
David Chiswell, Chief Executive Officer
Anne Hyland, Chief Financial Officer
Tel: +44 (0)1223 833 301
Email: [email protected]
Don Powell
Email: [email protected]
Tel: +44 (0)1223 515436
Mob: +44 (0)778 6858220
Consilium Strategic Communications
Mary-Jane Elliott/Jessica Hodgson/Suki Virji/Laura Thornton
Tel: +44 (0) 20 3709 5700
Email: [email protected]